Lavomax tablets 125mg, No. 10

• In adults: viral hepatitis A, B, C, herpes and CMV infection, complex therapy: infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis), chlamydial infections of the urogenital and respiratory tract;

• prevention of influenza, etc.

• ARVI.

• In children over 7 years of age: treatment of influenza and other acute respiratory viral infections.

Inside, after meals, for prophylactic purposes - 125 mg once a week for 4-6 weeks, with therapeutic - 125-250 mg / day for 1-2 days, then 125 mg every 48 hours.

Film-coated tablets from yellow to orange, round; the core of the tablet is orange.

1 tab.

tilorone dihydrochloride 125 mg

Excipients: magnesium hydroxycarbonate (heavy magnesium carbonate), povidone K30, calcium stearate.

• Hypersensitivity

• pregnancy,

• lactation period,

• children's age (up to 7 years).

pharmachologic effect

Low molecular weight synthetic interferon inducer that stimulates the formation of all types of interferons in the body (alpha, beta, gamma and lambda). The main producers of interferon in response to the administration of tilorone are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence intestines - liver - blood after 4-24 hours. Tilorone has an immunomodulatory and antiviral effect.

According to experimental studies, after a single oral administration of tilorone in a dose equivalent to the maximum daily dose for humans, Cmax in the lung tissue of interferon lambda is determined after 24 hours, interferon alpha - after 48 hours. Induction of interferon lambda in the lung tissue helps to increase the antiviral protection of the respiratory tract when influenza and other respiratory viral infections.

In human leukocytes, it induces the synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose, increases antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective against various viral infections, incl. against influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpes viruses. The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

Pharmacokinetics

Suction

After taking the drug inside, tilorone is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%.

Distribution

Plasma protein binding is about 80%.

Metabolism and excretion

Tilorone does not undergo biotransformation and does not accumulate in the body. It is excreted practically unchanged with feces (about 70%) and kidneys (about 9%). T1 / 2 is 48 hours.

Side effect

Possible: allergic reactions, dyspeptic symptoms, short-term chills.

If any of these side effects are aggravated, or the patient has noticed any other side effects, he should inform the doctor about it.

Application during pregnancy and lactation

The use of the drug during pregnancy is contraindicated. If it is necessary to use the drug during lactation, breastfeeding should be discontinued.

Application in children

Contraindicated in children and adolescents under 18 years of age.

special instructions

Influence on the ability to drive vehicles and mechanisms

The use of the drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Overdose

Overdose cases of LavomaxЃ are unknown.

Drug interactions

Compatible with antibiotics and traditional treatments for viral and bacterial diseases.

No clinically significant interaction of Lavomax * with antibiotics, means of traditional treatment of viral and bacterial diseases, or alcohol has been identified.